Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy

NCT01519700 is registered in ClinicalTrials.gov with Sandoz as lead sponsor.

NCT NCT01519700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01519700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
Lead sponsor
Sandoz
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
June 30, 2013
Enrollment
218 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy associated neutropenia